NEW YORK, Jan 14 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO: Quote, Profile, Research)(NVO.N: Quote, Profile, Research) said on Monday it was halting development of its AERx inhaled insulin product and will lay off most of the approximately 300 company employees working on the product.
